Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer

Gillessen, 2015, Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015, Ann Oncol, 26, 1589, 10.1093/annonc/mdv257 Diamond, 2014, Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies, J Clin Epidemiol, 67, 401, 10.1016/j.jclinepi.2013.12.002 Cristofanilli, 2004, Circulating tumor cells, disease progression, and survival in metastatic breast cancer, N Engl J Med, 351, 781, 10.1056/NEJMoa040766 Lorente, 2016, Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer, Eur Urol, 70, 985, 10.1016/j.eururo.2016.05.023 Leonie Z. The ACCEPT image analysis algorithm made for the Cancer-ID project. http://github.com/LeonieZ/ACCEPT. Business Wire. Circulating tumor cell (CTC) diagnostics market 2015-2022. Global strategic business report 2017—Research and Markets. www.businesswire.com/news/home/20170329005642/en/Circulating-Tumor-Cell-CTC-Diagnostics-Market-2015-2022. Lu, 2013, Decoding the androgen receptor splice variants, Transl Androl Urol, 2, 178 Antonarakis, 2016, Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting, Prostate Cancer Prostatic Dis, 19, 231, 10.1038/pcan.2016.17 Antonarakis, 2014, AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer, N Engl J Med, 371, 1028, 10.1056/NEJMoa1315815 Antonarakis, 2015, Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer, JAMA Oncol, 1, 582, 10.1001/jamaoncol.2015.1341 Scher, 2016, Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer, JAMA Oncol, 52, 1593 Lokhandwala, 2017, Analytical validation of androgen receptor splice variant 7 detection in a Clinical Laboratory Improvement Amendments (CLIA) laboratory setting, J Mol Diagn, 19, 115, 10.1016/j.jmoldx.2016.08.003 Taplin, 2017, Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-resistant prostate cancer (mCRPC), J Clin Oncol, 35, 5005, 10.1200/JCO.2017.35.15_suppl.5005 Del Re, 2017, The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients, Eur Urol, 71, 680, 10.1016/j.eururo.2016.08.012 Zhu, 2018, Novel junction-specific and quantifiable in situ detection of AR-V7 and its clinical correlates in metastatic castration-resistant prostate cancer, Eur Urol, 73, 727, 10.1016/j.eururo.2017.08.009 Wyatt, 2018, Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer, J Natl Cancer Inst, 110, 78 Romanel, 2015, Plasma AR and abiraterone-resistant prostate cancer, Sci Transl Med, 7, 312re10, 10.1126/scitranslmed.aac9511 Carreira, 2014, Tumor clone dynamics in lethal prostate cancer, Sci Transl Med, 6, 10.1126/scitranslmed.3009448 Wyatt, 2016, Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer, JAMA Oncol, 2, 1598, 10.1001/jamaoncol.2016.0494 Goodall, 2017, Circulating free DNA to guide prostate cancer treatment with PARP inhibition, Cancer Discov, 7, 1006, 10.1158/2159-8290.CD-17-0261 De Laere, 2017, Comprehensive profiling of the androgen receptor in liquid biopsies from castration-resistant prostate cancer reveals novel intra-AR structural variation and splice variant expression patterns, Eur Urol, 72, 192, 10.1016/j.eururo.2017.01.011 Khalaf, 2017, Circulating tumor DNA (ctDNA) and correlations with clinical prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC), J Clin Oncol, 35, 186, 10.1200/JCO.2017.35.6_suppl.186 Mateo, 2015, DNA-repair defects and olaparib in metastatic prostate cancer, N Engl J Med, 373, 1697, 10.1056/NEJMoa1506859 de Bono, 2016, PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC), Ann Oncol, 27, 7180 Chen, 2015, Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors, Clin Cancer Res, 21, 1273, 10.1158/1078-0432.CCR-14-1220 Li, 2011, Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression, Cancer Res, 71, 2108, 10.1158/0008-5472.CAN-10-1998 Li, 2012, AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression, Oncogene, 31, 4759, 10.1038/onc.2011.637 Nyquist, 2013, TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer, Proc Natl Acad Sci U S A, 110, 17492, 10.1073/pnas.1308587110 Abeshouse, 2015, The molecular taxonomy of primary prostate cancer, Cell, 163, 1011, 10.1016/j.cell.2015.10.025 Sita-Lumsden, 2013, Circulating microRNAs as potential new biomarkers for prostate cancer, Br J Cancer, 108, 1925, 10.1038/bjc.2013.192 Lawrie, 2008, Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma, Br J Haematol, 141, 672, 10.1111/j.1365-2141.2008.07077.x Huang, 2015, Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer, Eur Urol, 67, 33, 10.1016/j.eururo.2014.07.035 Zhang, 2011, Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy, Prostate, 71, 326, 10.1002/pros.21246 Lin, 2017, Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer, Br J Cancer, 116, 1002, 10.1038/bjc.2017.50 Scher, 2015, Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer, J Clin Oncol, 33, 1348, 10.1200/JCO.2014.55.3487 Armstrong, 2012, Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer, Eur Urol, 61, 549, 10.1016/j.eururo.2011.11.009 Khleif, 2010, AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development, Clin Cancer Res, 16, 3299, 10.1158/1078-0432.CCR-10-0880 Dougherty, 2012, Biomarker development: prudence, risk, and reproducibility, BioEssays, 34, 277, 10.1002/bies.201200003 Cummings, 2010, Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs, Br J Cancer, 103, 1313, 10.1038/sj.bjc.6605910 McShane, 2005, REporting recommendations for tumour MARKer prognostic studies (REMARK), Br J Cancer, 93, 387, 10.1038/sj.bjc.6602678 Norum, 2017, Treatments for metastatic prostate cancer (mPC): a review of costing evidence, Pharmacoeconomics, 35, 1223, 10.1007/s40273-017-0555-8